Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mirodenafil
- Development stage
- Phase 3
- Lead developer
- SK Chemicals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Mirodenafil is a second-generation, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor developed for the treatment of erectile dysfunction. It is a small molecule pyrrolopyrimidinone compound that works by inhibiting PDE5, thereby suppressing cGMP hydrolysis in cavernosal smooth muscle. This leads to smooth muscle relaxation and increased blood flow to the penis during sexual stimulation. Mirodenafil has higher selectivity for PDE5 compared to other PDEs and demonstrates greater selectivity over PDE6 than sildenafil, reducing the risk of visual side effects. It was approved in South Korea in 2007 for erectile dysfunction and has also been investigated for use in kidney diseases, urologic diseases, renal insufficiency, lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH), and Alzheimer’s disease due to its ability to cross the blood-brain barrier and modulate multiple signaling pathways relevant to neurodegeneration[2][3][4][5][6].
- Brand names
- Mvix
- Other names
- AR1001AR-1001AR 1001
02
Targets
GR (Glucocorticoid receptor)PDE5 (Phosphodiesterase 5A)
Beyond the preview
Go deeper on mirodenafil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mirodenafil.